An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 07 Sep 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2016 New trial record